Stereotaxis, Inc.

Stereotaxis, Inc. is a medical technology company specializing in innovative robotic systems for minimally invasive endovascular intervention. Headquartered in St. Louis, Missouri, the company's mission is to discover, develop, and deliver robotic systems, instruments, and information solutions for the interventional laboratory. These innovations aim to enable physicians to provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance efficiency and connectivity in the operating room.

The company's key products include Robotic Magnetic Navigation (RMN) systems such as the Genesis RMN System, GenesisX RMN System, and the Niobe ES system, which are designed to guide interventional tools with sub-millimeter precision. Stereotaxis also offers the Odyssey solution for real-time information management and the Synchrony System, which integrates cath lab systems and procedural information. Additionally, they develop robotically navigated magnetic ablation catheters like MAGiC and MAGiC Sweep, primarily used in cardiology for electrophysiology studies and cardiac catheter ablation procedures to treat arrhythmias.

Led by CEO and Chairman David L. Fischel, Stereotaxis is publicly traded on the NYSE American under the ticker STXS. Recent developments include the definitive agreement to acquire Robocath, announced on April 15, 2026, which will combine magnetic navigation with mechanical robotics to expand applications into interventional cardiology and neurointerventions. The company also announced FDA clearance and launch of its Synchrony System on April 6, 2026, and the first MAGiC procedures in the United States on April 22, 2026. Stereotaxis' technology has been utilized in over 100,000 procedures worldwide.